Use of Maribavir for Multidrug Resistant Cytomegaloviremia in a Pediatric Oncology Patient.
James E Fisher, Kevin Mulieri, Elizabeth Finch...
https://pubmed.ncbi.nlm.nih.gov/38447094/Actively Recruiting
Led by Takeda · Updated on 2026-05-22
80
Participants Needed
53
Research Sites
N/A
Total Duration
Researchers are studying the safety, tolerability, and how the body processes maribavir in children and teenagers who have cytomegalovirus CMV infection after receiving a hematopoietic stem cell transplant HSCT or a solid organ transplant SOT. This phase 3 trial aims to find the best dose of maribavir using either a 200 mg tablet or a powder for oral suspension formulation. The study focuses on these young patients who have documented CMV infection and evaluates maribavirs antiviral activity along with its pharmacokinetics. Participants receive maribavir for up to 8 weeks with doses adjusted based on age and body weight. For ages 12 to less than 18 years, dosing ranges from 100 mg to 400 mg twice daily depending on weight. Those aged 6 to less than 12 years follow a similar dosing scheme, and children younger than 6 years may receive doses from 50 mg once or twice daily up to 400 mg twice daily. The medication is taken orally as tablets or powder for oral suspension during the treatment period. During the study, participants will have multiple blood tests to measure maribavir levels at various time points, and adverse events will be monitored up to 20 weeks. There is a 12-week follow-up period after treatment ends, during which participants will visit their doctor to assess continued viral control and safety. Researchers will also evaluate the clearance of CMV viremia, recurrence rates, and resistance development, along with participant feedback on medication palatability.
CONDITIONS
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
T
Takeda Contact
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Takeda
Lead Sponsor
Takeda Development Center Americas, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Maribavir (oral antiviral, single-arm trial group) | Ganciclovir or valganciclovir (current guideline-recommended standard care) |
|---|---|---|
| What it is | Investigational oral antiviral drug (maribavir) administered to pediatric and adolescent transplant recipients with active CMV infection, including those with first episode or refractory disease. | Standard antiviral therapy for CMV infection in pediatric transplant recipients, typically based on intravenous ganciclovir or oral/IV valganciclovir, as recommended by current international guidelines. |
| Role in trial | Only intervention group; all enrolled participants receive maribavir as part of the single-group trial design. | External comparator; not part of the actual trial arms, but reflects usual care for eligible patients at this clinical decision point. |
| Primary use | Treatment of active CMV infection (including refractory cases) in pediatric or adolescent recipients of solid organ or hematopoietic stem cell transplants. | Treatment of active (including first-episode or reactivated) CMV infection following pediatric transplantation; administered as first-line therapy. |
| How it is given or performed | Administered orally at doses based on age and weight, as assigned by cohort (ranging from 50 to 400 mg, specific to age and body mass). | Ganciclovir is usually given intravenously; valganciclovir is available orally or intravenously. Dosage adapted by weight, renal function, and clinical protocols; treatment duration based on virologic and clinical response. |
| Evidence status | Evidence for maribavir in pediatric post-transplant CMV infection is limited to ongoing clinical trials and select case reports. Broader efficacy data exist for adults, but pediatric safety and antiviral activity remain under investigation. | Ganciclovir and valganciclovir are supported by extensive clinical evidence and guideline consensus for efficacy and safety as first-line therapy in pediatric post-transplant CMV infection. |
| Important limitations | Effectiveness and safety for pediatric transplant recipients are not yet established; results will depend on ongoing trial outcomes. Existing pediatric data are limited to a few case reports and early experience. Protocol excludes patients with severe organ dysfunction or certain concurrent treatments. | Ganciclovir and valganciclovir use may be limited by toxicity such as myelosuppression or renal effects, and CMV resistance can develop. Management may be complicated in patients unable to tolerate these drugs or experiencing drug interactions. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 8 weeks
Participants receive maribavir orally twice daily according to body weight for up to 8 weeks to treat CMV infection after stem cell or organ transplant.
Multiple visits including pharmacokinetic sampling on Day 7 (Week 1), Day 28 (Week 4), and Day 56 (Week 8)
Duration - Up to 12 weeks
Participants are monitored for safety, antiviral activity, and potential recurrence of CMV infection for up to 12 weeks after treatment ends.
Visits at Weeks 12, 16, and 20 post-treatment
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
3
Have more questions? Get in touch with our team for quick support
James E Fisher, Kevin Mulieri, Elizabeth Finch...
https://pubmed.ncbi.nlm.nih.gov/38447094/Takeda
Lead Sponsor
Takeda Development Center Americas, Inc.
Collaborating Sponsor